Home › NCT07284472
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
RecruitingPhase 2/3
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia
Who can join
Ages 55 to 90 · All sexes
Full eligibility criteria
Inclusion criteria: 1. The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair. 2. A previously established diagnosis of AD dementia. 3. The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization 4. The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation. 5. Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day. Exclusion criteria: 1. The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia. 2. The participant has symptoms of agitation that are not secondary to AD dementia 3. The participant has a history of uncontrolled seizures or a history of epilepsy. 4. The participant has a major medical illness or unstable medical condition
About the study
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
What is being tested
- EXV-802 (drug)
- Placebo (drug)
- EXV-801 (drug)
Sponsor: Exciva GmbH · Participants: 300 · Started: Feb 2, 2026
Contact the study team
- Exciva Clinical Studies · Phone: +49 6221-6479990
Official record on ClinicalTrials.gov — NCT07284472
Locations in the U.S.
| California | Esperanza Clinical, Murrieta |
| Indiana | Josephson Wallack Munshower Neurology PC, Indianapolis |
| Mississippi | Precise Research Centers, Flowood |
| Missouri | Galen Research LLC, Chesterfield (Not yet recruiting) |
| New York | Integrative Clinical Trials, Brooklyn Manhattan Behavioral Medicine, New York |
| Ohio | Insight Clinical Trials, Independence |
| Oregon | Oregon Health & Science University, Portland (Not yet recruiting) |
| Vermont | The Memory Clinic, Bennington |
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.